Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines
In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as MSD outside the U.S. and Canada, has ... Read More
LaNova Medicines, AstraZeneca sign $600m worth licensing deal for LM-305
LaNova Medicines has signed an exclusive license deal worth over $600 million for its pre-clinical stage antibody drug conjugate (ADC) called LM-305 with AstraZeneca. LM-305 ... Read More